What Isofundin Treats: Main Uses and Benefits

Isofundin is used to address conditions characterized by acute or unstable symptom patterns related to systemic imbalance. The solution is commonly used to help with significant deficits of extracellular fluid (isotonic dehydration), is applied in addressing derangements of essential electrolytes (Sodium, Potassium, Calcium, Magnesium), and supports the body’s acid-base balance when acidosis may be present.

It is typically applied in clinical settings that involve acute volume depletion, such as post-surgical care, trauma management, or replacement of severe gastrointestinal losses. The solution generally supports volume replacement, which can assist with maintaining functional stability and easing the physiological strain on the body during these difficult periods.

“This supportive function is relevant for managing systemic imbalance and may help contribute to easing distress during difficult acute episodes.”

Regulatory References

1. Official Summary of Product Characteristics

Isofundin's eligibility is strictly determined by regulatory rules defining which patient populations and medical conditions prohibit or restrict its use.

Populations for Whom Use is Established

Use is officially documented and established for adults, the elderly, adolescents, and children. The solution is generally considered acceptable for use in pregnant and lactating women in its intended indication, provided fluid and electrolyte balance is carefully monitored.

Absolute Contraindications (MUST NOT USE)

The medicine is strictly contraindicated and must not be administered in patients with:

• Hypervolaemia (fluid overload)
• Severe congestive cardiac failure
• Renal failure with oliguria (low urine output) or anuria (no urine output)
• Severe general oedema
• Hyperkalaemia (high blood potassium) or Hypercalcaemia (high blood calcium)
• Metabolic alkalosis

Eligibility-Related Restrictions and Cautions

Use requires special caution and careful monitoring in patients with less severe conditions, such as mild to moderate cardiac insufficiency or general impaired renal function (not severe failure). The regulatory label states that efficacy and safety have not been established for newborn infants (under 28 days of age).

Interactions with other medicines and products

The interaction profile for Isofundin is defined by the potential for additive electrolyte effects and specific administration constraints documented in regulatory labeling.

Pharmacodynamic and Additive Risk Interactions

Official prescribing information documents specific risks associated with the solution's electrolyte components. The co-administration of potassium-sparing diuretics (such as Amiloride, Spironolactone, or Triamterene), Suxamethonium, Tacrolimus, and Cyclosporine may result in an increase in plasma potassium concentration, which carries the risk of potentially fatal hyperkalaemia. This risk is specifically noted as increased in patients with renal failure.

Interactions related to the solution's calcium content are also documented: the effects of Digitalis glycosides may be enhanced during hypercalcaemia, which is associated with the risk of serious or fatal cardiac arrhythmia. This hypercalcaemia risk can also be induced by co-administered substances such as Vitamin D. Furthermore, the interaction with Corticoids/steroids and Carbenoxolone may be associated with the retention of sodium and water, resulting in edema and hypertension.

Administration Restriction

As a procedural constraint, the solution must not be administered via the same infusion set as concomitant blood transfusions.

Volume Restoration and Fluid Distribution

The primary mechanism is the volume expansion of the Extracellular Fluid (ECF) compartment through the physical action of infusion. As an isotonic crystalloid, Isofundin's osmolarity matches plasma, driving the passive, osmotic distribution of water and solutes across the capillary membranes. This physiochemical cascade restores hydrostatic pressure and influences circulating volume and the state of fluid balance.

Electrochemical Gradient Stabilization

The solution acts by providing a physiologically specific ratio of essential electrolytes ( Sodium, Potassium, Calcium, Magnesium) utilized by Cell Membrane Ion Transporters. This direct ion replacement affects the crucial electrochemical gradients across cell membranes required for cellular function. The ion replacement affects membrane potentials required for excitation-contraction coupling in cardiac and skeletal muscle tissue, and influences neuromuscular signal propagation.

Metabolic Acid- Base Buffering

The solution engages a metabolic pathway by supplying the anionic precursors Acetate and Malate. These are rapidly consumed in the Krebs Cycle of the liver and peripheral cells, which generates Bicarbonate ( HCO3^-). This synergistic dual- buffer mechanism chemically affects the concentration of protons ( H^+), thereby modulating the Strong Ion Difference (SID) and influencing systemic pH toward physiological neutrality.

How Isofundin is Used: Administration Guidelines

Isofundin is a Solution for Infusion, and its use follows specific prescribing parameters to ensure controlled and appropriate fluid replacement. The administration protocol focuses on the procedural instructions for delivery.

Routes and Form

Standard Dosing Volumes and Infusion Rate

Dosing is individualized by the treating clinician based on the patient's specific fluid and electrolyte needs. The dosage recommendations establish the upper and lower limits of the solution volume to be administered over 24 hours:

• Adults, Elderly, and Adolescents: The usual range is 500 ml to 3 litres per 24 hours.
• Infants and Children: The dosage is calculated based on body weight, typically ranging from 20 ml to 100 ml per kg body weight / 24 h.

Procedural and Age-Specific Instructions

The solution is administered continuously or in repeated infusions as long as there is a clinical need for fluid replacement. Key procedural rules are: only clear, particle-free solution should be used, and for rapid administration under pressure, all air must be withdrawn from the container and infusion set prior to starting the infusion. For newborn infants (below 28 days), safety and efficacy information has not been established.

Evidence for Fluid Replacement in Critical Care and Perioperative Settings

Research has extensively examined this type of balanced fluid in patients requiring fluid management during periods of acute volume loss, such as those in the Intensive Care Unit (ICU) or perioperative settings. Large-scale Randomized Controlled Trials (RCTs) and systematic reviews compared the solution to a standard saline comparator. Studies monitored hard clinical endpoints including patient mortality (30 and 90 days) and the incidence of Acute Kidney Injury (AKI). Findings were mixed; some studies observed a lower incidence of adverse kidney events compared to saline, while others reported no significant difference in overall mortality. The evidence indicates that certainty regarding a superior finding across all patient scenarios remains low.

Evidence for Managing Metabolic and Electrolyte Balance

The solution was studied to explore its potential relationship with the body's internal chemical environment, given its lower chloride content compared to standard saline. Research consistently reported measurements of lower serum chloride levels and a lower measured incidence of hyperchloremic metabolic acidosis. Studies also evaluated its use in acute conditions like Diabetic Ketoacidosis (DKA). However, studies have not yet established whether these observed biochemical changes (chloride and pH shifts) reliably translate into significant differences in major patient-focused hard clinical outcomes.

Follow-up Duration, Special Populations, and Research Gaps

Research primarily focuses on acute changes, with follow-up periods most often ranging up to 30 or 90 days. This means that long-term effects are not fully established. Studies have examined pediatric patients and specific subgroups like those with sepsis or Traumatic Brain Injury (TBI). In these special populations, findings were often mixed or remain insufficient due to trial heterogeneity. A key research limitation is that findings regarding major clinical endpoints continue to be inconsistent, and data for certain specific groups remain uncertain.

Key Studies & References

1. FICHA TÉCNICA ISOFUNDIN SOLUCIÓN PARA PERFUSIÓN (Summary of Product Characteristics, Spanish Regulatory Agency AEMPS)

Common questions about Isofundin (FAQ)

Q: How much sodium is in one litre of Isofundin?

Official product information, typically found in regulatory documents, specifies the exact composition of the solution. One litre of Isofundin contains 145 mmol of sodium. The solution’s components are intended to help restore and maintain the body's electrolyte balance.

Q: What do I do if I think I have received too much Isofundin (overdose)?

Regulatory information indicates that because this solution is administered in a controlled hospital setting by a healthcare professional, receiving an excessive dose is unlikely. If an overdose were to be suspected, official sources state that symptoms could include fluid accumulation in the lungs, shortness of breath, and changes in the fluid composition of the body. Management of an overdose would involve the healthcare team stopping the infusion and treating any resulting symptoms.

Q: Can Isofundin be mixed with other medications or additives in the same infusion bag?

The official administration instructions contain a key procedural restriction: Isofundin must not be mixed with or administered via the same infusion line as blood transfusions. For all other medicines, the official product information does not provide a general statement of compatibility. The decision to mix Isofundin with any other medicine remains the responsibility of the administering healthcare professional.

How to Store and Dispose of Isofundin?

Isofundin (Balanced Electrolyte Solution) must be stored and disposed of according to strict regulatory guidelines to maintain sterility and safety. All storage and disposal information is based on official product labeling.

This product is designated for single use only. Any unused portion of the solution remaining in the container after the infusion is complete must be immediately discarded. The medicine must not be used after its expiry date has passed.